DOI 10.1016/j.biochi.2026.06.014
Iron-acquisition-targeted therapy for multidrug-resistant Klebsiella pneumoniae: siderophore-antibiotic conjugates, clinical evidence, and emerging resistance.
Аннотация
Carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) (CRKP) is the top-ranked critical-priority pathogen on the 2024 WHO Bacterial Priority Pathogens List, and the convergence of carbapenem resistance with hypervirulence (CR-hvKP) is now reported across all WHO regions. Because K. pneumoniae is exquisitely dependent on iron for survival in the host, iron-acquisition pathways have emerged as a tractable target for therapeutic exploitation. Siderophore-antibiotic conjugates (SACs) hijack the bacterium's TonB-dependent transporters via a "Trojan-horse" mechanism, delivering the antibiotic warhead across the otherwise impermeable Gram-negative outer membrane. Cefiderocol, the first clinically approved SAC, has reshaped treatment options for metallo-β-lactamase-producing Enterobacterales, but emerging resistance via mutations in TonB-dependent transporters (notably cirA), regulators (envZ-ompR, baeSR), and β-lactamase amplification threatens its long-term utility. We critically synthesise advances spanning from 2020 to 2026 in K. pneumoniae iron biology, host nutritional immunity, SAC chemistry, real-world clinical evidence, and resistance mechanisms, and define a research agenda centred on the kinetic as well as transcriptional dynamics of K. pneumoniae under prolonged iron starvation that must be addressed to safeguard this therapeutic frontier.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.